TG Therapeutics Quarterly Cash Flow Statement
NASDAQ: TGTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
TG Therapeutics free cash flow
In the quarter ended Jun 30, 2026, TG Therapeutics generated $39.3 million of operating cash flow and spent $293,000 on capital expenditures. That left free cash flow of $39.0 million, a free-cash-flow margin of 16.2% of revenue. Free cash flow was up 427.0% from the prior year's $7.4 million.
Summary generated from market data by MetaCap's automated system. Methodology
TG Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 7.78M | 19.78M | 23.04M | 390.89M | 28.19M | 5.06M | 23.33M | 3.88M | 6.88M | -10.71M | -14.42M | 113.93M |
| Net Income growth (YoY) | -72.40% | +290.85% | -1.26% | +9974.61% | +309.75% | — | — | -96.59% | — | — | — | — |
| Depreciation & Amortization | 53.00K | 32.00K | 21.00K | 17.00K | 13.00K | 8.00K | 9.00K | 11.00K | 19.00K | 29.00K | 38.00K | 73.00K |
| Stock-Based Compensation | 27.88M | 19.95M | 15.65M | 17.69M | 16.36M | 14.97M | 11.95M | 11.77M | 9.48M | 9.34M | 9.38M | 9.18M |
| Change in Working Capital | -3.70M | -71.67M | -42.38M | -35.55M | -27.77M | -41.92M | -78.05M | -4.85M | -11.73M | -10.00M | -15.64M | -39.17M |
| Operating Cash Flow | 39.26M | -17.89M | 19.66M | -23.15M | 7.44M | -28.71M | -25.64M | -12.21M | 5.54M | -8.21M | -13.21M | 83.70M |
| Capital Expenditures | -293.00K | -51.00K | -67.00K | -80.00K | -42.00K | -25.00K | -21.00K | -24.00K | 0 | 0 | 0 | — |
| Investing Cash Flow | 1.03M | -9.86M | -15.64M | 46.36M | -3.99M | -12.93M | 15.79M | -9.33M | 1.76M | -9.26M | -44.76M | -30.23M |
| Share Repurchases | 0 | -99.99M | 0 | -78.24M | -6.88M | -6.12M | -6.61M | -2.15M | 0 | 0 | 0 | — |
| Debt Issued | 0 | 747.66M | 0 | 0 | 0 | 0 | 0 | 244.81M | — | — | 0 | 0 |
| Financing Cash Flow | 85.00K | 390.83M | 1.06M | -78.24M | -6.44M | -6.10M | -6.07M | 134.45M | 135.00K | 10.00K | -1.00K | 421.00K |
| Net Change in Cash | 40.38M | 363.07M | 5.08M | -55.03M | -3.00M | -47.75M | -15.93M | 112.92M | 7.44M | -17.45M | -57.97M | 53.90M |
| Free Cash Flow | 38.97M | -17.95M | 19.59M | -23.23M | 7.39M | -28.74M | -25.66M | -12.23M | 5.54M | -8.21M | -13.21M | 83.70M |
This table shows 12 quarterly periods of TG Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow TGTX's reporting calendar. What is a cash flow statement?